- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
Sage Therapeutic is a biotechnology business based in the US. Sage Therapeutic shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.91 – a decrease of 8.57% over the previous week. Sage Therapeutic employs 487 staff and has a trailing 12-month revenue of around $106.4 million.
What's in this guide?
Our top picks for where to buy Sage Therapeutic stock
- Trade $0 commission stocks, ETFs, and options with as little as $1
- After-hours trading available
- Earn 4.5% interest on uninvested cash with Gold
- 24/7 customer support
- $0 commission trading
- Instant withdrawals with a 1.75% fee
- Supports 250+ cryptocurrencies
- High-yield account earns up to 4.65% APY
Disclaimer: This page is not financial advice or an endorsement of digital assets, providers or services. Digital assets are volatile and risky, and past performance is no guarantee of future results. Potential regulations or policies can affect their availability and services provided. Talk with a financial professional before making a decision. Finder or the author may own cryptocurrency discussed on this page.
How to buy Sage Therapeutic stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – SAGE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Sage Therapeutic stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Sage Therapeutic stock price (NASDAQ: SAGE)
Use our graph to track the performance of SAGE stocks over time.Sage Therapeutic shares at a glance
Latest market close | $4.91 |
---|---|
52-week range | $5.09 - $28.26 |
50-day moving average | $7.05 |
200-day moving average | $12.56 |
Wall St. target price | $10.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-5.57 |
Is it a good time to buy Sage Therapeutic stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sage Therapeutic price performance over time
Historical closes compared with the close of $4.78 from 2024-11-18
1 week (2024-11-13) | -16.58% |
---|---|
1 month (2024-10-18) | -36.86% |
3 months (2024-08-20) | -42.75% |
6 months (2024-05-20) | -57.25% |
1 year (2023-11-20) | -75.76% |
---|---|
2 years (2022-11-18) | -86.71% |
3 years (2021-11-19) | 40.9 |
5 years (2019-11-20) | 151.52 |
Is Sage Therapeutic stock undervalued or overvalued?
Valuing Sage Therapeutic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sage Therapeutic's PEG ratio
Sage Therapeutic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sage Therapeutic financials
Revenue TTM | $106.4 million |
---|---|
Gross profit TTM | $-319,290,000 |
Return on assets TTM | -29.62% |
Return on equity TTM | -49.34% |
Profit margin | 0% |
Book value | $9.02 |
Market Capitalization | $328.5 million |
TTM: trailing 12 months
Sage Therapeutic share dividends
We're not expecting Sage Therapeutic to pay a dividend over the next 12 months.
Sage Therapeutic share price volatility
Over the last 12 months, Sage Therapeutic's shares have ranged in value from as little as $5.09 up to $28.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutic's is 0.924. This would suggest that Sage Therapeutic's shares are less volatile than average (for this exchange).
Sage Therapeutic overview
Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co. , Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc.
Frequently asked questions
What percentage of Sage Therapeutic is owned by insiders or institutions?Currently 11.905% of Sage Therapeutic shares are held by insiders and 87.008% by institutions. How many people work for Sage Therapeutic?
Latest data suggests 487 work at Sage Therapeutic. When does the fiscal year end for Sage Therapeutic?
Sage Therapeutic's fiscal year ends in December. Where is Sage Therapeutic based?
Sage Therapeutic's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Sage Therapeutic's ISIN number?
Sage Therapeutic's international securities identification number is: US78667J1088 What is Sage Therapeutic's CUSIP number?
Sage Therapeutic's Committee on Uniform Securities Identification Procedures number is: 78667J108
More guides on Finder
-
Robinhood Now Let’s You Trade on the Outcome of the Presidential Election; Joining Kalshi and others.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question